It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Mounjaro: Also contains tirzepatide and shares the same mechanism of action as Zepbound. It is branded for the treatment of Type 2 diabetes but is essentially the same compound as Zepbound.

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... HF market share if they offer a novel mechanism of action, enhanced clinical profiles or help ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity.

Zepbound: Recently FDA-approved in November 2023, it offers another option for patients seeking medical support for weight loss. Both medications have demonstrated excellent results in clinical ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...